Lexaria Bioscience (LEXX) Finished Goods (2018 - 2019)
Lexaria Bioscience (LEXX) posted Finished Goods of $41415.0 for Q1 2019, up 324.68% sequentially from $9752.0 in Q3 2018.
Lexaria Bioscience (LEXX) Finished Goods (2018 - 2019) Analysis & Trends
Lexaria Bioscience has reported Finished Goods for 2 years, with the latest figure at $41415.0 in Q1 2019.
- Quarterly Finished Goods changed N/A year-over-year to $41415.0 in Q1 2019, while the trailing twelve-month figure through Feb 2019 was $41415.0 (changed N/A YoY) and the FY2018 annual result came in at $9752.0, changed N/A from the prior year.
- Finished Goods rose to $41415.0 in Q1 2019 per LEXX's latest filing, from $9752.0 in the prior quarter.
- Over five years, Finished Goods peaked at $41415.0 in Q1 2019 and troughed at $9752.0 in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.79 Bn | 131.94 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.74 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn |
| 4 | Moderna | 59.32 Bn | 54.18 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.81 Bn | 28.50 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.56 Bn | 26.40 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - |
| 10 | Lexaria Bioscience | 10.36 Mn | 6.75 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2019 | 41,415.00 |
| Aug 31, 2018 | 9,752.00 |